The task force encourages men aged 55 to 69 to make an individualized decision about prostate cancer screening with their clinician, and recommends against screening men aged 70 years and older.
Read MoreA study has shown that Decipher Biopsy may accurately risk-stratify men for metastatic failure after first-line radiation and androgen deprivation therapy.
Read More
In blood samples from prostate cancer patients, researchers have found a group of circulating tumor cells that are linked to the spread of the disease.
Read More
The reclassifications have the potential to alter therapy decisions for patients following prostatectomy, by predicting whether an individual is at low, intermediate, or high risk of tumor metastasis.
Read MoreExperts have pointed out flaws in a recent study that received significant coverage in the lay media because of its implication of a “skyrocketing” increase in the incidence of metastatic prostate cancer.
Read More